Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Controlled release microparticles for vaccine development.

D T O'Hagan1, H Jeffery, M J Roberts

  • 1Department of Pharmaceutical Sciences, University of Nottingham, University Park, UK.

Vaccine
|October 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inclusivity of patients in early phase breast cancer clinical trials.

Journal of cancer policy·2024
Same author

Frontal sinus fracture management: a systematic review and meta-analysis.

International journal of oral and maxillofacial surgery·2020
Same author

The clinical efficacy of PSMA PET/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities and confirmatory histopathology: results of a single-centre, prospective clinical trial.

Clinical & experimental metastasis·2020
Same author

QTL analysis of cooking time and quality traits in dry bean (Phaseolus vulgaris L.).

TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik·2020
Same author

One man's wars.

Journal of the Royal Army Medical Corps·2018
Same author

Total temporomandibular joint replacement prostheses: a systematic review and bias-adjusted meta-analysis.

International journal of oral and maxillofacial surgery·2016
Same journal

Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.

Vaccine·2026
Same journal

Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial.

Vaccine·2026
Same journal

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026
Same journal

A historical overview of the anti-vaccine movement and its public health implications.

Vaccine·2026
Same journal

Vaccine strategies and development before and during the 1968 H3N2 influenza pandemic.

Vaccine·2026
Same journal

Influence of correlated vaccination behaviors on estimates of COVID-19 vaccine effectiveness in older adults - VISION network, October 2023 - March 2024.

Vaccine·2026
See all related articles

Biodegradable poly(lactide-co-glycolide) (PLGA) microparticles enhanced IgG antibody responses to ovalbumin (OVA) compared to soluble OVA. Adjuvant (FIA) further boosted responses, though Freund's complete adjuvant yielded the highest levels.

Area of Science:

  • Immunology
  • Biomaterials Science
  • Vaccine Development

Background:

  • Biodegradable microparticles offer a promising platform for antigen delivery.
  • Poly(lactide-co-glycolide) (PLGA) microparticles are widely studied for controlled release applications.
  • Ovalbumin (OVA) is a model antigen used in immunological studies.

Purpose of the Study:

  • To compare IgG antibody responses to ovalbumin (OVA) delivered via PLGA microparticles versus soluble OVA.
  • To evaluate the effect of Freund's incomplete adjuvant (FIA) on OVA-loaded PLGA microparticle immunogenicity.
  • To assess the long-term antibody response profiles.

Main Methods:

  • Rabbits were immunized with OVA encapsulated in PLGA microparticles, with or without FIA, or with soluble OVA.

Related Experiment Videos

  • Primary and secondary IgG antibody titers against OVA were measured over 84 days.
  • Comparisons were made between different delivery formulations and adjuvant combinations.

    • Main Results:

    • OVA in PLGA microparticles, especially with FIA, induced significantly higher primary IgG responses than soluble OVA.
    • Sustained elevated IgG responses were observed for microparticle formulations from day 49 to day 84.
    • While effective, OVA in PLGA microparticles/FIA generally elicited lower responses than OVA in Freund's complete adjuvant.

    Conclusions:

    • PLGA microparticles enhance systemic IgG antibody responses to entrapped antigens like OVA.
    • The addition of Freund's incomplete adjuvant further potentiates the immune response elicited by microparticle-delivered OVA.
    • PLGA microparticles represent a viable strategy for developing subunit vaccines, although adjuvant choice remains critical.